Medpace (NASDAQ:MEDP – Get Free Report) issued an update on its FY24 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $11.71-12.09 for the period, compared to the consensus estimate of $11.59. The company issued revenue guidance of $2.09-2.13 billion, compared to the consensus revenue estimate of $2.13 billion. Medpace also updated its FY 2024 guidance to 11.710-12.090 EPS.
Medpace Price Performance
Shares of MEDP stock opened at $326.54 on Wednesday. The company’s fifty day moving average price is $354.82 and its two-hundred day moving average price is $382.57. The firm has a market capitalization of $10.12 billion, a P/E ratio of 33.29, a P/E/G ratio of 1.77 and a beta of 1.35. Medpace has a 12 month low of $227.21 and a 12 month high of $459.77.
Medpace (NASDAQ:MEDP – Get Free Report) last released its quarterly earnings results on Monday, October 21st. The company reported $3.01 EPS for the quarter, topping the consensus estimate of $2.77 by $0.24. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The business had revenue of $533.32 million for the quarter, compared to analysts’ expectations of $540.99 million. During the same quarter in the previous year, the firm posted $2.22 earnings per share. The company’s revenue was up 8.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Medpace will post 11.64 EPS for the current year.
Wall Street Analysts Forecast Growth
Read Our Latest Report on MEDP
About Medpace
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Recommended Stories
- Five stocks we like better than Medpace
- Consumer Discretionary Stocks Explained
- UL Solutions Stock Breakout Imminent – Is Now the Time to Buy?
- Buy P&G Now, Before It Sets A New All-Time High
- GE Aerospace Margin Widens: Is It Time to Buy Dip?
- What is the Dogs of the Dow Strategy? Overview and Examples
- Rambus Stock Poised for Growth – Will the AI Boom Deliver?
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.